Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN)
NCT01735227 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 620
Last updated 2012-11-28
Summary
In order to further clarify the interaction of PPIs with clopidogrel anti - platelet effect , the investigators designed a clinical randomized controlled trials of omeprazole and pantoprazole antiplatelet effect of clopidogrel .In this experiment , the investigators have taken a randomized NSTE-ACS hospitalized patients met the inclusion criteria were randomly divided into omeprazole and pantoprazole groups . On the day of admission , all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg + aspirin 300mg and omeprazole group taking omeprazole 20mg / d , pantoprazole group taking pantoprazole 20mg / d. Respectively, on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization due to cardiovascular disease , bleeding events) . To assess the impact of PPIs on clopidogrel antiplatelet effect by observing 1 year follow-up results , and further explore the optimal combination of dual anti-platelet and joint PPIs course of treatment , appropriate dosage and the best time to provide reasonable for clinical programs to create a personalized treatment system , improve the patient's quality of life .
Conditions
- Acute Coronary Syndromes
Interventions
- DRUG
-
omeprazole
all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and omeprazole group taking omeprazole 20mg/d
- DRUG
-
Pantoprazole
On the day of admission , all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg + aspirin 300mg and omeprazole group taking omeprazole 20mg / d , pantoprazole group taking pantoprazole 20mg / d. Respectively, on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization
Sponsors & Collaborators
-
Yaling Han
lead OTHER
Principal Investigators
-
Han Yaling, MD · Shenyang Northern Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-11-30
- Primary Completion
- 2013-10-31
- Completion
- 2013-10-31
Countries
- China
Study Locations
More Related Trials
-
Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel
NCT01269333 ·Status: COMPLETED ·Phase: PHASE1
-
Influence Of Omeprazole On The Anti-Platelet Action Of Clopidogrel
NCT00349661 ·Status: COMPLETED ·Phase: PHASE3
-
Interaction Study of Clopidogrel 300/75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy Subjects
NCT01129388 ·Status: COMPLETED ·Phase: PHASE1
-
Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects
NCT01129414 ·Status: COMPLETED ·Phase: PHASE1
-
Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole
NCT01094275 ·Status: COMPLETED
-
"Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER-
NCT02028234 ·Status: UNKNOWN ·Phase: PHASE4
-
Influence of the Proton Pump Inhibitor Omeprazole on the Anti-Platelet of P2Y12 Antagonists in Subjects With Coronary and Peripheral Artery Disease
NCT01018940 ·Status: COMPLETED
-
Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel
NCT00405717 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Amlodipine on Anti-platelet Drug Effect in Patients With Coronary Artery Disease
NCT01203696 ·Status: COMPLETED ·Phase: PHASE4
-
Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine
NCT00950339 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540
NCT01557335 ·Status: COMPLETED ·Phase: PHASE1
-
Ranitidin Versus Omeprazole in Patients Taking Clopidogrel
NCT01896557 ·Status: COMPLETED ·Phase: PHASE4
-
Influence of Esomeprazole on Antiplatelet Action of Clopidogrel Associated With Aspirin
NCT01062516 ·Status: COMPLETED ·Phase: PHASE4
-
Cohort Study of Clopidogrel and Proton Pump Inhibitors
NCT01231867 ·Status: COMPLETED
-
Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients
NCT03078257 ·Status: UNKNOWN ·Phase: PHASE1
-
Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
NCT00557921 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects
NCT00930670 ·Status: COMPLETED ·Phase: PHASE4
-
Influence of Varenicline on the Antiplatelet Action of Clopidogrel
NCT01308671 ·Status: UNKNOWN ·Phase: NA
-
Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention
NCT00404781 ·Status: COMPLETED ·Phase: PHASE4
-
Peptic Ulcer Disease in Ischemic Heart Patients Taking Aspirin and Clopidogrel With or Without Proton Pump Inhibitor
NCT00854776 ·Status: UNKNOWN ·Phase: NA
-
Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.
NCT01175200 ·Status: COMPLETED ·Phase: NA
-
Effect of Proton Pump Inhibitor on Residual Platelet Reactivity After Clopidogrel in Homogenous Genetic Strata
NCT01512953 ·Status: UNKNOWN ·Phase: PHASE4
-
Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS
NCT02048228 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Prospective muLticEnter Registry in chrONic coronARy synDrOme
NCT06198673 ·Status: NOT_YET_RECRUITING
-
Relationship Between Dosage of Clopidogrel and Platelet Aggregation in Chinese With Different Genotype
NCT01710436 ·Status: UNKNOWN